OCCLUSIVE DEVICES WITH SPIRAL STRUTS FOR TREATING VASCULAR DEFECTS
20230240686 · 2023-08-03
Inventors
Cpc classification
A61B2017/12054
HUMAN NECESSITIES
A61B17/12177
HUMAN NECESSITIES
A61B17/12145
HUMAN NECESSITIES
A61B17/12172
HUMAN NECESSITIES
International classification
Abstract
Devices for treating vascular defects and associated systems and methods are disclosed herein. In some embodiments, for example, an occlusive device for treating an aneurysm includes a tubular structure having a first end portion with a first opening, a second end portion with a second opening, and a mesh surface extending between the first and second end portions. The occlusive device also includes a plurality of spiral struts coupled to the first end portion of the tubular structure and extending over the first opening. When the occlusive device is deployed within the aneurysm, the tubular structure and the plurality of spiral struts can be configured to self-expand such that the plurality of spiral struts span a neck of the aneurysm substantially within a single plane and the mesh surface of the tubular structure engages a wall of the aneurysm near the neck.
Claims
1.-51. (canceled)
52. An occlusive device for treating an aneurysm, the occlusive device comprising: a tubular structure having a first end portion with a first opening, a second end portion with a second opening, and a mesh surface extending between the first and second end portions; and a plurality of spiral struts coupled to the first end portion of the tubular structure and extending over the first opening, wherein, when the occlusive device is deployed within the aneurysm, the tubular structure and the plurality of spiral struts are configured to self-expand such that the plurality of spiral struts span a neck of the aneurysm substantially within a single plane and the mesh surface of the tubular structure engages a wall of the aneurysm near the neck.
53. The occlusive device of claim 52, wherein the tubular structure comprises a stent including a plurality of cells.
54. The occlusive device of claim 52, wherein the tubular structure comprises a braid formed from a plurality of filaments.
55. The occlusive device of claim 52, wherein the plurality of spiral struts are arranged in a radial configuration.
56. The occlusive device of claim 52, further comprising a hub, wherein each spiral strut includes a first end region coupled to the hub, and a second end region coupled to the first end portion of the tubular structure.
57. The occlusive device of claim 56, wherein the second end region of each spiral strut is coupled to a peripheral edge of the tubular structure.
58. The occlusive device of claim 52, further comprising a detachment element configured to releasably couple the tubular structure and the plurality of spiral struts to a pusher member.
59. The occlusive device of claim 58, further comprising a hub, wherein the detachment element is coupled to the plurality of spiral struts via the hub.
60. The occlusive device of claim 59, further comprising an elongate member connecting the detachment element to the hub, wherein the elongate member is configured to transform from a first state to a second state when the occlusive device is deployed within the aneurysm.
61. The occlusive device of claim 60, wherein: when in the first state, the elongate member extends away from the tubular structure, and when in the second state, the elongate member is positioned at least partially within the tubular structure.
62. The occlusive device of claim 52, wherein, when the occlusive device is deployed within the aneurysm, the plurality of spiral struts are contained entirely within the aneurysm.
63. An occlusive device for treating an aneurysm, the occlusive device comprising: a tubular structure having a first end portion and a second end portion opposite the first end portion; a plurality of curved struts coupled to the first end portion of the tubular structure, each curved strut including a first end region and a second end region; and a hub, wherein the plurality of curved struts are arranged in a spiral configuration with the first end region of each curved strut coupled to the hub, and the second end region of each curved strut coupled to the first end portion of the tubular structure.
64. The occlusive device of claim 63, wherein the tubular structure comprises a stent.
65. The occlusive device of claim 63, wherein the tubular structure comprises a braid.
66. The occlusive device of claim 63, wherein the second end region of each curved strut is coupled to a peripheral edge of the tubular structure.
67. The occlusive device of claim 66, wherein the second end region of each curved strut is spaced apart along the peripheral edge of the tubular structure.
68. The occlusive device of claim 63, wherein the first end portion of the tubular structure includes a first opening, and the plurality of curved struts are disposed over the first opening.
69. The occlusive device of claim 63, wherein the tubular structure and plurality of curved struts are configured to self-expand when deployed within the aneurysm.
70. The occlusive device of claim 63, wherein, when deployed within the aneurysm, the plurality of curved struts are disposed across a neck of the aneurysm and the tubular structure engages a wall of aneurysm near the neck.
71. The occlusive device of claim 63, wherein, when deployed within the aneurysm, the plurality of curved struts lie substantially within a single plane.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present disclosure.
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
DETAILED DESCRIPTION
[0049] The present technology relates to devices for treating vascular defects such as aneurysms, and associated systems and methods. In some embodiments, for example, an occlusive device for treating an aneurysm includes a tubular structure (e.g., a tubular stent or braid) having a first end portion with a first opening, a second end portion with a second opening, and a mesh surface extending between the first and second end portions. The occlusive device can also include a plurality of spiral struts coupled to the first end portion of the tubular structure and extending over the first opening. When the occlusive device is deployed within the aneurysm, the tubular structure and the plurality of spiral struts can self-expand such that the plurality of spiral struts span a neck of the aneurysm and the mesh surface of the tubular structure engages a wall of the aneurysm near the neck.
[0050] The occlusive devices of the present technology can provide many advantages compared to conventional device for treating an aneurysm. For example, the use of spiral struts enables the occlusive device to expand outward to conform to different neck geometries, while keeping the struts substantially in-plane with the aneurysm neck and/or out of the parent vessel. Accordingly, the occlusive devices disclosed herein can be used to treat a wider range of aneurysm sizes (e.g., aneurysms having a neck diameter from 3 mm to 5 mm) and/or shapes (e.g., aneurysm necks having a non-circular shape, such as oblong or peanut-shaped), as well as challenging aneurysm types such as wide-necked aneurysms (e.g., aneurysms having a neck diameter greater than 4 mm and/or a dome-to-neck ratio less than 2). Additionally, the spiral struts can brace the tubular structure radially outward against the wall of the aneurysm near the neck, thus reducing the likelihood of the device becoming dislodged and/or prolapsing into the parent vessel. Once deployed, the devices herein can be contained partially or entirely within the aneurysm sac with little or no protrusion into the parent vessel, thus reducing the likelihood of clot formation and/or avoiding the need for concomitant DAPT.
[0051] Embodiments of the present disclosure will be described more fully hereinafter with reference to the accompanying drawings in which like numerals represent like elements throughout the several figures, and in which example embodiments are shown. Embodiments of the claims may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. The examples set forth herein are non-limiting examples and are merely examples among other possible examples.
[0052] As used herein, the terms “vertical,” “lateral,” “upper,” and “lower” can refer to relative directions or positions of features of the embodiments disclosed herein in view of the orientation shown in the Figures. For example, “upper” or “uppermost” can refer to a feature positioned closer to the top of a page than another feature. These terms, however, should be construed broadly to include embodiments having other orientations, such as inverted or inclined orientations where top/bottom, over/under, above/below, up/down, and left/right can be interchanged depending on the orientation.
[0053]
[0054] The device 100 includes a tubular structure 102 coupled to a plurality of curved struts 104. The tubular structure 102 is configured to anchor the device 100 at or near the neck of the aneurysm, while the curved struts 104 are configured to retain an embolization element within the device 100, as described in further detail below. The tubular structure 102 includes a proximal end portion 106, a distal end portion 108, and a mesh surface 110 extending between the proximal end portion 106 and distal end portion 108. In some embodiments, the proximal end portion 106 and distal end portion 108 each have a respective opening, such that the tubular structure 102 includes a lumen extending between the proximal end portion 106 and distal end portion 108, and surrounded by the mesh surface 110. The length L of the tubular structure 102 (e.g., as measured from the proximal end portion 106 to the distal end portion 108 when the device 100 is fully expanded) can be no more than 4 mm, 3.5 mm, 3 mm, 2.5 mm, 2 mm, 1.5 mm, or 1 mm. The width W or diameter of the tubular structure 102 (e.g., as measured when the device 100 is fully expanded) can be at least 5 mm, 4.5 mm, 4 mm, 3.5 mm, 3 mm, 2.5 mm, 2 mm, 1.5 mm, or 1 mm. Although
[0055] In the embodiment of
[0056] The curved struts 104 are connected to the proximal end portion 106 of the tubular structure 102. As best seen in
[0057] In some embodiments, each curved strut 104 includes a first end region 116 (e.g., a proximal end region) coupled to a hub 120 and a second end region 118 (e.g., a distal end region) coupled to the proximal end portion 106 of the tubular structure 102. The second end region 118 of each curved strut 104 can be coupled to a proximal apex 119 of a respective cell 114 of the tubular structure 102. In other embodiments, however, the second end region 118 can be coupled to a different portion of the cell 114, such as to a lateral edge of the cell 114. The hub 120 can be generally aligned with the center of the opening of the proximal end portion 106, and the second end regions 118 of the curved struts 104 can be spaced apart along the peripheral edge of the proximal end portion 106, such the separation distance between the curved struts 104 increases as the curved struts 104 radiate outward from the hub 120. The spacing between the curved struts 104 can be sufficiently large to permit an embolization element delivery device (e.g., a microcatheter or other elongate shaft) to pass through, but sufficiently small such that the embolization element does not prolapse into the parent vessel. In some embodiments, the average and/or maximum distance between neighboring curved struts 104 is no more than 2.5 mm, 2.25 mm, 2 mm, 1.75 mm, 1.5 mm, 1.25 mm, 1 mm, 0.75 mm, or 0.5 mm.
[0058] The configuration of the curved struts 104 can be varied in many different ways.
[0059] For example, although
[0060] Referring to
[0061] In the illustrated embodiment, the hub 120 is a collar, band, ring, etc., that crimps or otherwise holds the first end regions 116 of the curved struts 104 together. Alternatively, the hub 120 can simply be the location where the first end regions 116 are connected to each other (e.g., via welding, bonding, adhesives), rather than a separate component. As best seen in
[0062] Optionally, the device 100 can include one or more radiopaque portions so the physician can visualize the location and configuration of the device 100 during deployment in the aneurysm. For example, radiopaque markers (not shown) can be incorporated into the device 100 at or near the distal apices 115, at or near the proximal apices 119, at or near the intersections of adjacent cells 114, at or near the second end regions 118 of the curved struts 104, at or near the first end regions 116 of the curved struts 104, and/or on or within the hub 120.
[0063] The device 100 can be manufactured in many different ways. For example, the tubular structure 102 and/or curved struts 104 can be formed by laser-cutting of a tube or sheet, etching, metal injection molding, braiding, or any other suitable manufacturing process. In some embodiments, the tubular structure 102 and curved struts 104 are integrally formed as a single unitary component. In other embodiments, the tubular structure 102 and curved struts 104 can be discrete components that are attached to each other, e.g., using welding, adhesives, fasteners, or other suitable techniques. The tubular structure 102 and/or curved struts 104 can be formed of known flexible materials, including shape memory and/or superelastic materials (e.g., Nitinol), cobalt chromium, platinum, stainless steel, other metals or metal alloys, or a combination thereof. Optionally, portions of the tubular structure 102 and/or curved struts 104, or the entirety of the tubular structure 102 and/or curved struts 104, can include one or more coatings or surface treatments, such as coatings or treatments to increase lubricity and/or reduce the delivery force as the device 100 is advanced through the delivery catheter, increase hydrophilicity, and/or enhance blood compatibility and reduce thrombogenic surface activity. For example, an anti-thrombogenic coating or treatment can be applied to the curved struts 104, hub 120, and/or detachment element 122.
[0064] In some embodiments, the device 100 is configured to transform between a first, low-profile configuration suitable for delivery via an elongate shaft (e.g., a delivery catheter) and a second, expanded configuration suitable for bridging the neck of an aneurysm (e.g., the configuration illustrated in
[0065]
[0066] Referring first to
[0067] Referring next to
[0068] Referring next to
[0069] Referring next to
[0070] Referring next to
[0071] Referring next to
[0072] The coil 212 can have a length from 2 cm to 30 cm, from 3 cm to 25 cm, or from 4 cm to 20 cm. In some embodiments, the length of the coil 212 depends on the size of the aneurysm being treated. For example: for an aneurysm 4 mm in diameter or less, the coil 212 can have a length of about 6 cm; for an aneurysm 5 mm in diameter or less, the coil 212 can have a length of about 8 cm; for an aneurysm 6 mm in diameter or less, the coil 212 can have a length of about 15 cm; for an aneurysm 7 mm in diameter or less, the coil 212 can have a length of about 15 cm; for an aneurysm 8 mm in diameter or less, the coil 212 can have a length of about 20 cm; and, for an aneurysm 9 mm in diameter or less, the coil 212 can have a length of about 20 cm.
[0073] The coil 212 can be made from metals, alloys, polymers, shape memory materials (e.g., Nitinol), platinum, rhodium, palladium, tungsten, gold, silver, cobalt-chromium, platinum tungsten, and/or various alloys of these materials. In some embodiments, the coil 212 is heat set to form a tertiary structure (e.g., a pre-determined three-dimensional structure) when in a deployed state. For example, the coil 212 can have a preset tertiary structure that biases the coil into a bundled or more globular state that facilitates positioning of the coil 212 between the deployed device 100 and the aneurysm wall. In other embodiments, however, the coil 212 may not have a tertiary structure.
[0074] As previously mentioned, embolic coils such as the coil 212 can be very effective at filling space within the aneurysm cavity. However, there is a risk that the coil 212 may prolapse through the neck N of the aneurysm A into the vessel V, particularly if the aneurysm A is a wide-necked aneurysm. The device 100 can address this challenge via the curved struts 104 that are positioned over the aneurysm neck N to support the coil 212 and prevent the coil 212 from protruding into the neck, while the tubular structure 102 braces against the aneurysm wall to resist the outward pressure toward the vessel V exerted by the packed coil 212 so the device 100 does not bulge into the vessel V.
[0075] The methods of the present technology can be performed under fluoroscopy such that the radiopaque portions of the device 100 can be visualized by the physician to ensure proper neck coverage. If the device 100 is not positioned properly, the physician can withdraw the device 100 into the first elongate shaft 202, reposition, and deploy again. Additionally, in embodiments where the coil 212 is radiopaque, the physician can use fluoroscopy to confirm that the coil 212 does not protrude from the neck N of the aneurysm A after deployment.
[0076]
[0077] Referring to
[0078]
[0079] Referring again to
[0080] Referring next to
[0081] In some embodiments, some or all of the filaments 426 (e.g., at least 25%, 50%, 80%, or 100% of the filaments 426) are made of one or more shape memory and/or superelastic materials (e.g., Nitinol). The braid can have, for example, from 32 to 144 filaments 426, such as 64 or 72 filaments 426. Some or all of the filaments 426 can have a diameter from 0.0010 inches to 0.0012 inches, such as a diameter of 0.0010 inches, 0.0011 inches, or 0.0012 inches (at least prior to etching). In some embodiments, some or all of the filaments 426 are drawn-filled tubes (“DFT”) having a radiopaque core (e.g., platinum) surrounded by a shape memory alloy and/or superelastic alloy (e.g., Nitinol, cobalt chromium, etc.). Radiopaque markers can alternatively or additionally be incorporated into other portions of the device 400, e.g., at or near the distal end portion 408, proximal end portion 406, curved struts 404, hub 420, etc. All or a portion of the length of some or all of the filaments 426 can have one or more coatings or surface treatments. For example, some or all of the filaments 426 can have a lubricious coating or treatment that reduces the delivery force as the device 400 is advanced through the delivery catheter. In some embodiments, the coating is relatively hydrophilic, such as a phosphorocholine compound. Additionally or alternatively, some or all of the filaments 426 can have a coating or treatment (the same as the lubricious coating, or a different coating) that enhances blood compatibility and reduces the thrombogenic surface activity of the braid. Optionally, at least a portion of the filaments 426 can be made of other suitable materials.
[0082] In some embodiments, the tubular structure 402 and curved struts 404 are integrally formed as a single unitary component. For example, the curved struts 404 can be formed from the same filaments 426 used to form the braid of the tubular structure 402. In such embodiments, each curved strut 404 can be made from one or more filaments 426 that are bundled, twisted, braided, or otherwise assembled into a single elongate component. Alternatively, the tubular structure 402 and curved struts 404 can be discrete components that are attached to each other, e.g., using welding, adhesives, fasteners, or other suitable techniques. In such embodiments, the curved struts 404 can be formed of known flexible materials, including shape memory and/or superelastic materials (e.g., Nitinol), cobalt chromium, platinum, stainless steel, other metals or metal alloys, or a combination thereof, and can be manufactured by laser-cutting, etching, metal injection molding, braiding, etc.
CONCLUSION
[0083] Although many of the embodiments are described above with respect to systems, devices, and methods for treating a cerebral aneurysm, the technology is applicable to other applications and/or other approaches. For example, the occlusive devices, systems, and methods of the present technology can be used to treat any vascular defect and/or fill or partially fill any body cavity or lumen or walls thereof, such as for parent vessel take down, endovascular aneurysms outside of the brain, arterial-venous malformations, embolization, atrial and ventricular septal defects, patent ductus arteriosus, and patent foramen ovale. Additionally, several other embodiments of the technology can have different states, components, or procedures than those described herein. It will be appreciated that specific elements, substructures, advantages, uses, and/or other features of the embodiments described can be suitably interchanged, substituted or otherwise configured with one another in accordance with additional embodiments of the present technology. A person of ordinary skill in the art, therefore, will accordingly understand that the technology can have other embodiments with additional elements, or the technology can have other embodiments without several of the features shown and described above with reference to
[0084] The descriptions of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Where the context permits, singular or plural terms may also include the plural or singular term, respectively. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology, as those skilled in the relevant art will recognize. For example, while steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.
[0085] As used herein, the terms “generally,” “substantially,” “about,” and similar terms are used as terms of approximation and not as terms of degree, and are intended to account for the inherent variations in measured or calculated values that would be recognized by those of ordinary skill in the art.
[0086] Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. As used herein, the phrase “and/or” as in “A and/or B” refers to A alone, B alone, and A and B. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded.
[0087] It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with certain embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.